Clinical Trials Browser

Noninsulin-dependent diabetes mellitus with deafness × Plasma cell × Clear all

NCT01383759 2020-04-07

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Phase NA Completed

20 enrolled 16 charts

Noninsulin-dependent diabetes mellitus with deafness, Immunoglobulin Light-chain Amyloidosis, Amyloidosis